<![CDATA[Brukinsa access program extended to reach about 1,000 CLL patients]]>
A global program curated by the partnership of BeOne Medicines, its BeOne Care Foundation and The Max Foundation that expands access to the blood cancer drug Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) in low- and middle- …